Abstract
Non-immunosuppressive immunophilin ligands (NI-IPLs) are attracting attention as new candidate drugs for neuroprotection and / or neurorestoration, particularly since they do not have the adverse effects of immunosuppressants. However, it is not yet enough to understand that NI-IPLs are useful drugs for treating neurological disorders. In particular, the molecular mechanism of NI-IPL activity in target cells in the brain remains obscure. In this review, we focused on the molecular basis of the neuroprotective properties of IPLs. Our findings suggest that IPLs have neuroprotective effects mediated by multiple beneficial properties such as a glutathione (GSH)-activating effect, a neurotrophic factor (NTF)-activating effect, and an anti-apoptotic effect, but not by an immunosuppressive effect, both in cell cultures and in vivo. In particular, the GSH-activating effect and the NTF-activating effect of NI-IPLs may be essential to the expression of their neuroprotective properties. Thus, NI-IPLs might have a potentially beneficial effect by ameliorating neurological disorders, since they do not cause serious side effects such as immune deficiency.
Keywords: neuroimmunophilins, non-immunosuppressive immunophilin ligand, glutathione, gdnf, bdnf, apoptosis
Current Pharmaceutical Design
Title: Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Volume: 10 Issue: 6
Author(s): K. Tanaka and N. Ogawa
Affiliation:
Keywords: neuroimmunophilins, non-immunosuppressive immunophilin ligand, glutathione, gdnf, bdnf, apoptosis
Abstract: Non-immunosuppressive immunophilin ligands (NI-IPLs) are attracting attention as new candidate drugs for neuroprotection and / or neurorestoration, particularly since they do not have the adverse effects of immunosuppressants. However, it is not yet enough to understand that NI-IPLs are useful drugs for treating neurological disorders. In particular, the molecular mechanism of NI-IPL activity in target cells in the brain remains obscure. In this review, we focused on the molecular basis of the neuroprotective properties of IPLs. Our findings suggest that IPLs have neuroprotective effects mediated by multiple beneficial properties such as a glutathione (GSH)-activating effect, a neurotrophic factor (NTF)-activating effect, and an anti-apoptotic effect, but not by an immunosuppressive effect, both in cell cultures and in vivo. In particular, the GSH-activating effect and the NTF-activating effect of NI-IPLs may be essential to the expression of their neuroprotective properties. Thus, NI-IPLs might have a potentially beneficial effect by ameliorating neurological disorders, since they do not cause serious side effects such as immune deficiency.
Export Options
About this article
Cite this article as:
Tanaka K. and Ogawa N., Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease, Current Pharmaceutical Design 2004; 10 (6) . https://dx.doi.org/10.2174/1381612043453135
DOI https://dx.doi.org/10.2174/1381612043453135 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets 5-Lipoxygenase in the Central Nervous System: Therapeutic Implications
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Biological Activities of Eco-Friendly Synthesized Hantzsch Adducts
Medicinal Chemistry Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology The Application of Nanomaterials in Stem Cell Therapy for Some Neurological Diseases
Current Drug Targets Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets
Current Medicinal Chemistry Perfusion MRI of Brain Neoplams
Current Medical Imaging TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Diarylurea: A Privileged Scaffold in Drug Discovery and Therapeutic Development
Current Medicinal Chemistry In Vivo Monitoring of Cell Based Therapy in the Liver
Current Molecular Imaging (Discontinued) Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Boronated DNA-Binding Compounds as Potential Agents for Boron Neutron Capture Therapy
Mini-Reviews in Medicinal Chemistry Multi Fractal Process of Powder Particle Breakage and Aggregation
Current Nanoscience The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Modulation of Matrix Metalloproteinases by Plant-derived Products
Current Cancer Drug Targets A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry